anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic granulomatous disease (CGD) is a rare genetic immune disorder that results in recurrent and severe infections, and inflammatory dysregulation. For almost 50% of patients with CGD, this inflammation causes severe inflammatory bowel disease (IBD). However, treatment is long term and challenging as CGD-IBD is prone to relapse, and use of immune modulators must be balanced with increased risk of infectious complications. Conventional IBD (Crohn disease and ulcerative colitis) is likely caused by an inappropriate inflammatory response to intestinal microbes, which is influenced by the environment in a genetically susceptible host. While it is not yet clear if intestinal dysbiosis is a result or cause of intestinal inflammation, studies suggest that correcting intestinal dysbiosis may improve intestinal inflammation. Studies in patients with conventional IBD suggest that strict dietary restrictions can resolve symptoms of IBD and induce remission as effectively as glucocorticoids but without the side effects of those drugs. Because these diets alter the gut microbiome, they may serve as effective treatment for CGD-IBD.

In this study, we propose to treat 5 patients \>= 8 years old who have CGD and IBD with 4 weeks of an elemental diet. Participants will stay as inpatients for up to 2 weeks and will return for follow-up at the end of the diet to begin tapering off and be reintroduced to normal food. The primary objective of this study is the evaluation of changes in the microbiome before and after the elemental diet. Secondary objectives are evaluations of tolerability and safety of the diet, along with changes in local and systemic markers of inflammation, and improvement of IBD symptoms as determined by reduction in Harvey-Bradshaw Index score.
### Pregnancy “Category D” 

Bleomycin can cause fetal harm when administered to a pregnant woman. It has been shown to be teratogenic in rats. Administration of intraperitoneal doses of 1.5 mg/kg/day to rats (about 1.6 times the recommended human dose on a unit/m2 basis) on days 6 to 15 of gestation caused skeletal malformations, shortened innominate artery and hydroureter. Bleomycin is abortifacient but not teratogenic in rabbits at intravenous doses of 1.2 mg/kg/day (about 2.4 times the recommended human dose on a unit/m2 basis) given on gestation days 6 to 18. 

There have been no studies in pregnant women. If bleomycin is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant during therapy with bleomycin.
BACKGROUND: Value-based healthcare (VBHC) is increasingly implemented in healthcare worldwide. Transparent measurement of the outcomes most important and relevant to patients is essential in VBHC, which is supported by a core set of most important quality indicators and outcomes. Therefore, the aim of this study was to develop a VBHC-burns core set for adult burn patients.
METHODS: A three-round modified national Delphi study, including 44 outcomes and 24 quality indicators, was conducted to reach consensus among Dutch patients, burn care professionals and researchers. Items were rated on a nine-point Likert scale and selected if ≥ 70% in each group considered an item 'important'. Subsequently, instruments quantifying selected outcomes were identified based on a literature review and were chosen in a consensus meeting using recommendations from the Dutch consensus-based standard set and the Dutch Centre of Expertise on Health Disparities. Time assessment points were chosen to reflect the burn care and patient recovery process. Finally, the initial core set was evaluated in practice, leading to the adapted VBHC-burns core set.
RESULTS: Twenty-seven patients, 63 burn care professionals and 23 researchers participated. Ten outcomes and four quality indicators were selected in the Delphi study, including the outcomes pain, wound healing, physical activity, self-care, independence, return to work, depression, itching, scar flexibility and return to school. Quality indicators included shared decision-making (SDM), the number of patients receiving aftercare, determination of burn depth, and assessment of active range of motion. After evaluation of its use in clinical practice, the core set included all items except SDM, which are assessed by 9 patient-reported outcome instruments or measured in clinical care. Assessment time points included are at discharge, 2 weeks, 3 months, 12 months after discharge and annually afterwards.
CONCLUSION: A VBHC-burns core set was developed, consisting of outcomes and quality indicators that are important to burn patients and burn care professionals. The VBHC-burns core set is now systemically monitored and analysed in Dutch burn care to improve care and patient relevant outcomes. As improving burn care and patient relevant outcomes is important worldwide, the developed VBHC-burns core set could be inspiring for other countries.
One of the most effective ways of preventing lethal graft-versus-host disease (GVHD) after allogeneic bone marrow transplantation (BMT) for leukemia is to remove T-lymphocytes from the transplanted marrow. The reduced early mortality from T cell depletion is however offset by an increased risk of leukemic relapse and infection. We have shown that bone marrow transplants for leukemia depleted of T cells by elutriation and followed by delayed add-back of donor T cells reduces GVHD while preserving an immune response to the hematologic malignancy (the so-called graft-versus-leukemia (GVL) or graft-versus-myeloma effect). The study highlighted a possible benefit of large doses of marrow progenitor cells on transplant outcome. GVHD was reduced but not prevented by T cell depletion of the marrow. The first objective of our BMT studies is to prevent GVHD from the transplant while conserving GVL reactivity. This is a prerequisite to our second objective of determining the risk of GVHD and the benefit from GVL from add-back of donor lymphocytes. These studies will provide the basis for a planned trial adding back donor lymphocytes selected in vitro to confer immunity against infectious agents and residual leukemia without causing GVHD.

In this study we will evaluate the use of T cell depleted peripheral blood progenitor cells (PBPC) (instead of bone marrow) to optimize the stem cell and lymphocyte dose. Donors will be given G-CSF and their mobilized PBPC harvested by leukapheresis. To minimize acute GVHD, the transplant will be T cell depleted, using a new technique developed in normal volunteers which improves T cell depletion and reduces stem cell loss (protocol 96-H-0049). The study has two phases: The first phase evaluates engraftment and GVHD following T cell depleted PBPC transplants. Stopping rules will be used to make modifications to the protocol in the event of graft failure. Cyclosporine will be withdrawn from the protocol if the incidence of acute GVHD is low or absent. In the second phase patients will receive add-back of donor lymphocytes on day 45 and day 100 post transplant to prevent relapse and confer donor-immune function. The risk of acute GVHD following this procedure will be determined. It is planned to treat up to 55 patients aged between 10 and 60 years. The end points of the study are graft take; acute and chronic GVHD, leukemic relapse, transplant-related and all causes of mortality, cytomegalovirus reactivation and leukemia-free survival. Patients will be followed for 5 years.
The invention discloses a preparation method and application of chicken homologous specific serum and immunoglobulin. A technical scheme comprises preparation of immunogen; preparation of specific serum; preparation of immunoglobulin and virus inactivation and activity detection. The invention employs a meat chicken immunization method to produce specific serum and immunoglobulin which are prepared into a passive immunity preparation. A meat chicken can obtain immunization protection capability immediately after taken the passive immunity preparation. The passive immunity preparation has characteristics of substantial curative effect, rapid drug effect and no toxic or side effect, and is easy for preservation, convenient for transport and with a long shelf life. Besides, the production technology is simple and suitable for industrialized production.
The present invention relates to antimicrobial compositions and methods for their use. In particular, the compositions comprise an antimicrobial agent and a nanostructured liquid crystal carrier, wherein the antimicrobial agent is contained within the nanostructured liquid crystal carrier, and wherein the nanostructured liquid crystal carrier potentiates the activity of the antimicrobial agent. Antimicrobial agents encompassed by the present invention include cationic antibiotics, antimicrobial peptides, and antifungal agents. Nanostructured liquid crystal carriers encompassed by the present invention include those formed from an amphiphilic lipid such as monoolein and phytantriol. Antimicrobial compositions encompassed by the present invention can be used for the treatment or prevention of a microbial infection, such as that caused by a Gram-negative bacterium, including where the microbial infection forms part of a biofilm. The present invention also relates to methods for reducing the viability of a microorganisms, for potentiating the activity of an antimicrobial agent, for reducing the dose of an antimicrobial agent required to treat or prevent a microbial infection, or for increasing the potency of an antimicrobial agent required to treat or prevent a microbial infection, by administering an antimicrobial composition described herein. Kits comprising the antimicrobial compositions are also encompassed by the present invention.
BACKGROUND: Cutaneous squamous cell carcinoma (cSCC) frequently occurs in photoexposed areas. Surgery remains the mainstay of treatment in attempts to reduce recurrence, but it must be combined with other therapy because of the limited excision possible in the region of the eyelid, lip, and nose. Photodynamic therapy (PDT) is a relatively new treatment modality that involves the administration of a photosensitizing drug and its subsequent activation by specific wavelengths of light to produce reactive oxygen species that specifically destroy target cells.
CASE REPORT: An 87-year-old female presented 4 weeks after initial resection with recurrent medium-differentiated cSCC measuring 5.2 cm × 3 cm × 2 cm in the left upper eyelid. Subsequent treatment involved palliative resection with an additional 1 cm at 3 margins of the tumor (excluding the bottom edge of the double eyelid line) and 3 applications of PDT using 5-aminolevulinic acid as the photosynthesizing agent in the open wound over a 2-week period. The wound healed well within 6 weeks. During the following 4 years, the patient showed satisfactory progress in both aesthetics and function, with no sign of recurrence or metastasis.
CONCLUSION: Refractory cSCC was successfully managed using a combination of PDT and secondary healing, and functions of the head and face were well protected. These results suggest that such management warrants consideration in clinical settings.
Self monitoring of blood glucose level is crucial in diabetes management, so it is important to increase compliance of blood glucose checking. Lancet which is currently available methods have shown low compliance of self monitoring of blood glucose, since it causes pain, keratinization of finger tip, secondary infection. The purpose of this study is evaluating laser lancing device which cause much less pain than lancet to increase compliance of blood sugar checking, and to establish self monitoring system for patients of chronic diseases.

The investigators recruit total of 80 subjects who visit Korea University Medical center Guro and Ansan hospital. Study subject are type 2 diabetes whose glycated hemoglobin level is more than 6.5% and less than 8.5%, and whose age is more than 20 years and under 80 years. Subjects are randomly distributed in group A or B. Group A subjects use laser device to check blood glucose for 2 months, then take a month for wash out period. After wash out period, participants use lancet for following 2 months. Group B subjects use lancet first, then have a month for wash out period, after then, switch to laser device afterwards. During washout period, participants use usual glucose checking method which subjects had used. The investigators evaluate the number of blood glucose measurement, glycated hemoglobin, diabetes distress scale, average pain score, average satisfaction score from each group. Also the investigators compare blood glucose, liver function test, lipid level between values from one hand measured by lancet, and values from the other hand measured by laser lancing device.
After anesthetic induction, AuraGain is inserted for airway management. Size of the device is selected according to the manufacturer's recommendation; size 1.5 for 5-10kg, size 2 for 10-20kg.
PROBLEM TO BE SOLVED: To obtain a tubulin polymerization inhibitor useful as a therapeutic agent associated with hyperplasia such as rheumatism and cancer as well as a fundamental analytical reagent by including pironetin or analog thereof as active ingredient. SOLUTION: This tubulin polymerization inhibitor is obtained by including pironetin produced by Streptomyces actinomycetes isolated from soil, an analog thereof (e.g. demethylpironetin, epoxypironetin) or a pharmacologically acceptable salt thereof. Its administration mode may be oral or parenteral, its dosage form being e.g. tablets, powder. Its clinical daily dose as a cell cycle inhibitor or antitumor agent is normally 0.1 mg to 1 g or so per adult in one to several portions.
Men will not utilize PTT for the first 6 months post-prostatectomy. Beginning at 6 months, they may utilize PTT if they desire (open label) until 9 months post-prostatectomy.
Necrotizing soft tissue infection (NSTI) is a life-threatening illness that can seriously harm a person. Over the last years the incidence of NSTI has increased. A rapid and thorough debridement is crucial to let patients survive. After this debridement, patients will often end up with large skin defects. A burn center is specialized in treating skin defects. Patients with large skin defects after the acute phase of NSTI can be referred to this for a multidisciplinary approach. In this article we describe the surgical treatment of the complex wounds of three referred patients with NSTI in our burn center.
Ultraviolet (UV) radiation can lead to skin damage and cancer. Ultraviolet A (UVA) irradiation is 10 to 100 times more abundant in natural sunlight than ultraviolet B (UVB), thus human skin is exposed to more UVA irradiation daily.UVA irradiation is not completely filtered by clothing and it penetrates deeper into the dermis than UVB, potentially causing more damage. It is believed that skin cancer, photo aging, and skin immunomodulation are mediated by the reactive oxygen species (ROS) that are generated in response to UV radiation. Singlet oxygen (1O2) is one type of ROS. The aim of this study is to quantify the level of singlet oxygen generated in the skin after exposure to UVA radiation. Previous studies have used low dose ultraviolet A1(UVA1) irradiation of 20 J/cm2, which mimics exposure to strong sunlight of approximately two hours. This study will use UVA doses equivalent to or less than what humans are exposed to in daily life. Additionally, the aim is to quantify singlet oxygen produced in individuals of various skin types before and after application of sunscreens containing zinc oxide and avobenzone (sun protection factor 30). To our knowledge, there is no method for quantifying singlet oxygen in human skin after exposure to UVA light. This is a novel method that may help the investigators understand further the protective effects of various skin types, as well as sunscreens.
A growing body of research has established a correlation between tumors and persistent chronic inflammatory infiltration. As a primary instigator of inflammation, the majority of microbiomes naturally residing within our bodies engage in a mutually beneficial symbiotic relationship. Nevertheless, alterations in the microbiome's composition or breaches in the normal barrier function can disrupt the internal environment's homeostasis, potentially leading to the development and progression of various diseases, including tumors. The investigation of tumor-related microbiomes has contributed to a deeper understanding of their role in tumorigenesis. This review offers a comprehensive overview of the microbiome alterations and the associated inflammatory changes in ovarian cancer. It may aid in advancing research to elucidate the mechanisms underlying the ovarian cancer-associated microbiome, providing potential theoretical support for the future development of microbiome-targeted antitumor therapies and early screening through convenient methods.
A vaccine comprises an mRNA polynucleotide encoding a coronavirus antigen, and an amphipathic cell penetrating RALA peptide. The vaccine may comprise up to three mRNA polynucleotides, which may encode SARS-CoV-2 antigens such as the Membrane, Envelope, Spike, and/or Nucleoprotein antigens. The polynucleotides may be present in an equal or unequal copy ratio. The vaccine may have an immunoadjuvant such as a cytokine or granulocyte-macrophage colony-stimulating factor. The mRNA polynucleotide may comprise N1-methylpseudouridine nucleotides and unmodified cytidine nucleotides. The vaccine may comprise nanoparticles. The N:P ratio of amphipathic cell penetrating peptide:mRNA polynucleotide may be about 8.5-9.5:1. The vaccine may further comprise trehalose. A method of preparing a nanoparticle formulation of the vaccine in an automated mixing system is also provided. The vaccine may be used to treat coronavirus infection, particularly SARS-CoV-2. A method of treating COVID-19 is also provided. The RALA complexed mRNA nanoparticles may have improved intracellular delivery of the mRNA cargo, protecting it from degradation, and may be readily lyophilised whilst maintaining function.
The invention relates to a kudzuvine root gas-containing solid beverage piece and a preparation process thereof. The kudzuvine root gas-containing solid beverage piece is prepared from the following raw materials: 150-250g of kudzuvine root powder, 700-900 g of lactose, 8-15 g of stevioside, 120-150 g of tartaric acid, 180-220 g of citric acid, 3-5 g of taste rectifying agent, 180-220 g of polyethylene glycol, 360-400 g of sodium bicarbonate and 50-70 g of talcum powder; the raw materials are made into 1,000 beverage pieces. The preparation process comprises the following steps that: the kudzuvine root powder, the lactose, the stevioside, the citric acid and the tartaric acid are taken to be well mixed; ethanol is used for preparing a core material; the polyethylene glycol is heated, added to the sodium bicarbonate, cooled, ground, added to and mixed with the core material; the taste rectifying agent is ground, added to and mixed with the core material, added to and mixed with the talcum powder and then compressed into pieces. The preparation process uses a modern technique to make the kudzuvine root into gas-containing solid beverage pieces. The beverage piece reasonably loads beneficial composition in the kudzuvine root, can promote salivation, quench thirst, prevent and treat diseases, has strong health care function, applies to various populations, and is convenient to take, good in taste, easy to carry, transport and keep and long in storage period. The beverage piece is a novel kudzuvine root health care beverage.
Cerebral ischemia is a devastating condition that results in impaired blood flow in the brain leading to acute brain injury. As the most common form of stroke, occlusion of cerebral arteries leads to a characteristic sequence of pathophysiological changes in the brain tissue. The mechanisms involved, and comorbidities that determine outcome after an ischemic event appear to be highly heterogeneous. On their own, the processes leading to neuronal injury in the absence of sufficient blood supply to meet the metabolic demand of the cells are complex and manifest at different temporal and spatial scales. While the contribution of non-neuronal cells to stroke pathophysiology is increasingly recognized, recent data show that microglia, the main immune cells of the central nervous system parenchyma, play previously unrecognized roles in basic physiological processes beyond their inflammatory functions, which markedly change during ischemic conditions. In this review, we aim to discuss some of the known microglia-neuron-vascular interactions assumed to contribute to the acute and delayed pathologies after cerebral ischemia. Because the mechanisms of neuronal injury have been extensively discussed in several excellent previous reviews, here we focus on some recently explored pathways that may directly or indirectly shape neuronal injury through microglia-related actions. These discoveries suggest that modulating gliovascular processes in different forms of stroke and other neurological disorders might have presently unexplored therapeutic potential in combination with neuroprotective and flow restoration strategies.
Risk Summary

Based on limited data after oral administration, rilpivirine is present in human breast milk. The data do not allow determination of the amount of rilpivirine that is transferred to milk. There are no data on the presence of cabotegravir in human milk. Cabotegravir is present in animal milk (see Data). When a drug is present in animal milk, it is likely that the drug will be present in human milk. It is not known if the components of CABENUVA affect human milk production or have effects on the breastfed infant. Residual exposures in human milk of cabotegravir (if present) and rilpivirine may remain for 12 months or longer after the last injections have been administered [see Warnings and Precautions (5.6)].

Potential risks of breastfeeding include: (1) HIV‑1 transmission (in HIV-1–negative infants), (2) developing viral resistance (in HIV-1–positive infants), and (3) adverse reactions in a breastfed infant similar to those seen in adults.

Data

Cabotegravir: Animal lactation studies with cabotegravir have not been conducted. However, cabotegravir was detected in the plasma of nursing pups on Lactation Day 10 in the rat pre- and postnatal development study.
The present invention discloses a simulated epitope peptide of MUC1 mucoprotein, and coding DNA and applications of the peptide. The present invention aims at providing a simulated epitope peptide of MUC1 mucoprotein, coding DNA thereof, and the applications of the simulated epitope peptide to the preparation of vaccines and medicine for resisting tumors. The simulated epitope peptide is a polypeptide with one of the following amino acid residue sequences: 1) SEQ ID No. 1 in a sequence table and 2) a polypeptide with specific cells for inducing the generation of MUC1 mucoprotein and the function of humoral immune response, wherein the 2) polypeptide is formed by replacing or deleting or adding one to ten amino acid residue of the amino acid residue sequence of the SEQ ID No. 1. The coding DNA is one of the following nucleotide sequences: 1) a DNA sequence of SEQ ID No. 2 in the sequence table and 2) a nucleotide sequence which can form hybridization with the DNA sequence limited by the SEQ ID No. 2 in the sequence table under high precise conditions. The peptide of the present invention can be used as active ingredients for preparing vaccines or medicine, and can perform the functions for restraining or clearly expressing tumour cells of MUC1. The present invention has wide application prospect in the field of medicine.